Study of Response in Chronic Hepatitis C (CHC) Participants Genotype 1 With Insulin Resistance and Prolonged Treatment Duration in Late Responders (P04823/MK-4031-303)

NCT00493805 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

59

Enrollment

INDUSTRY

Sponsor class

Stopped Slow Enrollment

Conditions

Hepatitis C, Chronic
Insulin Resistance

Interventions

DRUG: Combination of pegylated interferon alfa-2b and ribavirin
DRUG: Combination of pegylated interferon alfa-2b and ribavirin

Sponsor

Merck Sharp & Dohme LLC